The U.S. Centers for Disease Control and Prevention (CDC) launched the Emerging Infections Program (EIP) in 1995 to develop centers of excellence in infectious disease surveillance and applied public health research in selected state health departments across the United States.
In addition to core surveillance activities, each of the four programs (ABCs, Foodnet, Influenza, and HAI) participates in special studies designed to evaluate: risk factors for disease, effectiveness of vaccines, success of public health interventions, and new methodologies for improving public health surveillance systems.
On this page:
Active Bacterial Core Surveillance
13-Valent Pneumococcal Conjugate Vaccine (PCV13) Effectiveness
A vaccine effectiveness evaluation of PCV13 against invasive pneumococcal disease (IPD) caused by vaccine serotypes in the population of children recommended to receive PCV13. It is expected that the vaccine will be highly effective at preventing IPD, even in children who do not receive the full four-dose schedule.
Quadrivalent Meningococcal Conjugate Vaccine (MCV4) Effectiveness
An effectiveness evaluation of MCV4 against invasive meningococcal disease (IMD) caused by vaccine-preventable serogroups (A, C, Y, W135), and the serogroupspecific effectiveness of MCV4 against serogroups C and Y meningococcal disease among adolescents.
Implementation of Perinatal Group B Streptococcal Prevention Guidelines among Infants with Invasive Early-Onset Infections
Traceback investigation evaluating the implementation of perinatal GBS prevention guidelines to identify implementation failures among early‐onset GBS cases and to assess factors that may contribute to a false negative antenatal GBS screen.
Foodborne Diseases Active Surveillance Network
Identifying human genomic factors associated with the development of hemolytic uremic syndrome (HUS) among persons infected with Shiga-toxin producing E. coli (STEC) and calculate the proportion of disease risk attributable to these genetic factors. Cases with STEC infections are asked for a saliva sample, which is then analyzed for genetic markers.
Non-O157 STEC Case-Control
Identifying behavioral, environmental, dietary, and medical risk factors for non-O157 Shiga toxin-producing E. coli infection and to describe clinical and microbiological features of illnesses caused by different types of non-O157 STEC.
Influenza Hospital Surveillance
Trivalent Invactivated Influenza Vaccine (TIV) Effectiveness
The TIV study is a multi-state study funded by CDC to determine the effectiveness of TIV among persons 50 and older in preventing laboratory confirmed hospitalizations.
EIP/HAI Point Prevalence
The Emerging Infections Program (EIP)/Healthcare-Associated Infections (HAI) and Antimicrobial Use Prevalence Survey is a one-day survey of antimicrobial use in up to 250 hospitals at ten different sites across the US including California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee.
Denominator Simplification Project
Though surveillance of HAIs is very important for understanding and reducing the problem, it can take a large amount of time to collect complete data. Limited resources and inability to collect denominator data on a routine basis are recognized barriers to conducting HAI surveillance. As a result CDC, in collaboration with EIP designed the Denominator Simplification Project to find ways to collect this data efficiently.